Selinexor Finds Its Place in the Evolving Multiple Myeloma Treatment Arsenal
A comprehensive review redefines how selinexor, the first oral XPO1 inhibitor, fits into modern myeloma therapy for hard-to-treat patients.
Summary
Multiple myeloma treatment has advanced dramatically, yet remains incurable for many patients, particularly those with high-risk genetics or drug resistance. Selinexor, the first oral selective inhibitor of exportin 1 (XPO1), offers a novel mechanism of action and is approved in combination regimens for relapsed/refractory myeloma. This Italian expert review synthesizes current evidence on selinexor's mechanism, drug interactions, emerging combinations, and its place in treatment sequencing. The authors highlight its consistent efficacy across difficult subgroups — including triple-class refractory patients, those with kidney dysfunction, high-risk cytogenetics, and prior anti-CD38 exposure — while addressing strategies to manage toxicity and improve adherence. Selinexor is positioned as a particularly valuable option for patients ineligible for T-cell-redirecting therapies.
Detailed Summary
Multiple myeloma therapy has been transformed over two decades, with deeper remissions and longer survival now achievable. However, the disease remains incurable, and subgroups including patients with high-risk cytogenetics, renal impairment, or early drug resistance still face poor outcomes. Novel agents with distinct mechanisms of action are urgently needed to address these gaps.
Selinexor is the first-in-class oral selective inhibitor of exportin 1 (XPO1), a nuclear export protein whose overactivation allows cancer cells to suppress tumor suppressor proteins. By blocking XPO1, selinexor forces retention of these proteins in the nucleus, restoring their anti-tumor function. It carries regulatory approval as selinexor-bortezomib-dexamethasone (for patients with ≥1 prior line) and selinexor-dexamethasone (for heavily pretreated patients).
This expert consensus review from a large Italian collaborative group examines selinexor's mechanism, its pharmacological interactions with proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and emerging partners like CAR-T and bispecific antibodies. The authors also review strategies for mitigating common toxicities such as nausea, thrombocytopenia, and fatigue, which have historically limited adherence.
Key clinical implications include selinexor's documented activity in triple-class refractory myeloma, patients with renal dysfunction — a population often excluded from trials — and those with high-risk cytogenetic features. The drug's oral bioavailability is a practical advantage, particularly for frail or elderly patients. The review positions selinexor as especially relevant for patients who cannot receive T-cell-redirecting therapies (bispecifics or CAR-T), where treatment alternatives are limited.
Caveats include the review's reliance on existing trial data without new primary findings, and acknowledged conflicts of interest among authors with ties to multiple pharmaceutical companies. Ongoing trials are expected to further define selinexor's optimal sequencing and combinatorial role.
Key Findings
- Selinexor, an oral XPO1 inhibitor, is approved for relapsed/refractory myeloma in two combination regimens.
- Consistent efficacy observed in triple-class refractory, renal-impaired, and high-risk cytogenetic patient subgroups.
- Selinexor is highlighted as a key option for patients ineligible for T-cell-redirecting therapies.
- Toxicity management strategies — including dose modification and antiemetics — can improve treatment adherence.
- Novel selinexor combinations with bispecific antibodies and other agents are under active investigation.
Methodology
This is a narrative expert review and consensus paper authored by a large Italian hematology collaborative. It synthesizes published clinical trial data, approved indications, and emerging combination strategies rather than reporting new primary data. The authors represent major Italian academic and clinical hematology centers.
Study Limitations
As a review paper, no new clinical data are generated, and conclusions depend on the quality and generalizability of cited trials. Multiple authors disclosed significant financial relationships with pharmaceutical companies, introducing potential bias. Definitive sequencing recommendations await results from prospective trials evaluating selinexor in combination with newer agents.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: